Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL
A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.